Phase 1/2 Clinical Trial Expected to Launch in 2H'22 and Will Evaluate the Safety and Preliminary Antitumor Activity of OTX-2002 CAMBRIDGE, Mass., July 14, 2022 /PRNewswire/ -- Omega Therapeutics Inc. (Nasdaq: OMG...
OTX-2002 is currently under clinical evaluation in the Phase 1/2 MYCHELANGELO™ I trial in adult patients with HCC and other MYC-associated solid tumors (NCT05497453). About the OMEGA platform The OMEGA platform leverages the Company’s deep understanding of gene regulation, genomic architecture ...
These results provide clinical proof of mechanism of the epigenomic controller platform and support continued development of OTX-2002.Clinical trial information: NCT05497453.Jonathan MizrahiDepartment of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LAWilliam Senapedis...
Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26 CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) --Omega Therapeutics, Inc. (Nasda...
progress and design of our Phase 1/2 MYCHELANGELOTMI clinical trial and our preclinical studies, as well as the anticipated impact and application of preliminary data related thereto; the potential of the OMEGA platform to engineer programmable epigenomic mRNA ther...
The Company plans to initiate a Phase 1 clinical trial in the U.S. to evaluate OTX-2002, following FDA clearance. About OTX-2002 OTX-2002 is a first-in-class Omega Epigenomic Controller™ in develop...